导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.68% | 1837/4773 |
| 近一周 | -0.66% | 230/5462 |
| 近一月 | 3.58% | 136/5421 |
| 近一季 | 2.86% | 424/5209 |
| 近半年 | -0.66% | 1354/4920 |
| 近一年 | 1.62% | 2302/4366 |
| 近两年 | 23.75% | 2548/2954 |
| 近三年 | 22.83% | 1372/2253 |
| 成立以来 | 100.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.65% 1222/4961 |
-10.08% 4040/5312 |
- - |
- - |
| 2025 | 3.94% 3081/4813 |
-0.78% 2407/3635 |
5.88% 530/4076 |
-3.89% 4012/4524 |
2.95% 807/4813 |
| 2024 | 20.75% 444/3463 |
10.24% 71/2808 |
3.76% 249/3014 |
6.06% 2871/3129 |
-0.47% 1431/3463 |
| 2023 | 10.43% 96/2656 |
8.01% 504/2280 |
2.07% 170/2385 |
4.10% 160/2515 |
-3.77% 785/2655 |
| 2022 | 2.47% 26/2207 |
5.24% 36/1919 |
1.04% 1507/2016 |
-1.29% 19/2113 |
-2.38% 1803/2208 |
| 2021 | 17.80% 223/1822 |
6.38% 93/1255 |
5.00% 830/1330 |
9.77% 131/1466 |
-3.92% 1464/1822 |
| 2020 | 8.87% 851/1250 |
-11.34% 837/1028 |
6.46% 864/1067 |
11.75% 428/1164 |
3.21% 935/1184 |
| 2019 | - - |
- - |
- - |
- - |
7.99% 368/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华泰柏瑞中证红利低波ETF联接C VS. 长安沪深300非周期A(740101) |